Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
about
Interferon alpha for chronic hepatitis DAntiviral drugs for viruses other than human immunodeficiency virusDirect acting antivirals for the treatment of chronic viral hepatitisMagnetic resonance elastography of liver: technique, analysis, and clinical applications.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Rapid acquisition technique for MR elastography of the liver.Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis.Development and evaluation of a baseline-event-anticipation score for hepatitis deltaAmeliorative effect of bone marrow-derived stem cells on injured liver of mice infected with Schistosoma mansoniQuantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus-associated hepatocellular carcinoma.Meta-analysis: antiviral treatment for hepatitis D.Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analysesIneffective CD8(+) T-cell immunity to adeno-associated virus can result in prolonged liver injury and fibrogenesis.Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosisOptimizing management strategies in special patient populations.Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year ExperienceManagement of chronic hepatitis B: consensus guidelinesTherapeutic advances in the management of chronic hepatitis B infection.Treatment of chronic hepatitis D.Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysisHepatitis D Virus: A Call to Screening.Current therapy for hepatitis C or D or immunodeficiency virus concurrent infection with chronic hepatitis B.Deactivation of hepatic stellate cells during liver fibrosis resolution in mice.Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation.Treatment of HBV-related cirrhosis.SASLT practice guidelines for the management of hepatitis B virus.Interferon alpha-2b therapy in chronic hepatitis deltaDendritic cells in alcoholic liver injury and fibrosis.Treatment of special populations with chronic hepatitis B infection.Control of ADAR1 editing of hepatitis delta virus RNAsTreatment of delta hepatitis.Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis.Management and treatment of chronic hepatitis B in HIV-positive patients.SILAC-based quantitative proteomic analysis of secretome between activated and reverted hepatic stellate cells.Emerging challenges in managing hepatitis B in HIV patients.Therapy of Delta Hepatitis.Treatment of Delta Hepatitis: Today and in the Future - A review.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
P2860
Q24234444-0DD166DC-67EF-4006-B1C7-5FA02A4F124CQ24635330-826B246F-8AF5-483C-84F6-3B6BD181A816Q27022216-13D6FF64-515C-4041-89ED-92D535B9C4CDQ27027849-DE9DA80B-679B-4733-8C49-62714F31462FQ30391932-DC171075-8B9B-4BC1-AAEF-A09080F32E5CQ30430184-D949B3EE-2E85-4126-B17A-849A79A65F78Q30443462-299EBA29-B262-4C68-8103-D35997C56E70Q33414249-D9962BAB-D762-44BC-B59A-C6766395198AQ33639255-2E649D62-12E3-4CAB-9A08-11912CDB3FD5Q33859188-0C3D93DA-1B52-4227-A6AD-0F2697AD9E9BQ34079748-352B8790-E23F-4627-AEDD-B55A3DDFA14DQ34138307-D09B0FEB-134E-46AF-BD88-56DB541B6A7BQ34203972-35FCC31C-AA53-4BB3-9D63-877F2F39AB32Q35475399-58230449-2CE7-401E-AD74-C3D8333475B0Q36188436-70A52ABE-A36B-45A1-89C3-8D3929EA43D2Q36237963-E2D81C1A-9BC0-40EF-8030-1AF126C339A0Q36382644-B1A070C2-5DE0-49CD-924C-71A74D3313CFQ36717966-4A5DD3F1-6EEE-402B-AD88-79FC26F7BC08Q36849343-7416B3EE-105D-4E87-9069-8097465DE86AQ36971785-A6A1CA98-6EFA-41A6-9070-DD4D2801A792Q36980735-62D5B02F-51C5-411D-B37E-62D78A4401A4Q37117293-C990A407-AD97-4D4A-8351-8E7861D5DC5EQ37182821-49AB9FD8-4EF7-4FE2-9077-A6BA83AAEF26Q37278249-1ECF493A-6033-485C-8457-094F7BE4F478Q37358947-1DCB83A2-5E23-4408-A03F-4385899F6981Q37386506-10F44042-21F6-4824-AA18-4AF32F722B83Q37503332-2136F007-D4F0-4E22-ADCD-5793CAADA235Q37634822-C0F54D39-8DAD-4E26-B814-AACF6BFEE53FQ37707363-18D261FC-3BEB-42CE-889F-73114DA2A7AEQ37834041-0E558646-0239-4257-9AE9-7528AB93B504Q37886158-F573EE8E-39AF-447E-9C60-E0BAE2DFA09EQ37898051-BB6B47FC-C37E-4301-9695-BB71C5984DEDQ38102778-13D1F9CA-D373-4389-BB8D-429532DB717CQ38119225-A08AB0E6-9862-4040-AFA2-B9FD278D811CQ38203324-8323EE19-A321-48C0-9E1C-F1692BB20C90Q38427366-C180934F-9189-4660-A925-201D9715A0DBQ38544189-742BE713-3177-4666-98BA-C1BFA61A47D1Q38562544-A9D630EE-5C53-414B-B822-B7188B16DBC9Q38769975-DD3C5573-8505-4E02-8853-F3B51CF4CD3DQ38962101-2005C1EF-044C-4C57-9817-24CCA6786F75
P2860
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@en
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@nl
type
label
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@en
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@nl
prefLabel
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@en
Long-term benefit of interfero ...... of advanced hepatic fibrosis.
@nl
P2093
P1433
P1476
Long-term benefit of interfero ...... n of advanced hepatic fibrosis
@en
P2093
Angelo Balestrieri
Anna Paola Mazzoleni
Giancarlo Serra
Giovanna Peddis
Luciano Caruso
Maria Eliana Lai
Maurizio Loy
Patrizia Farci
Robert H Purcell
Rosetta Scioscia
P304
P356
10.1053/J.GASTRO.2004.03.017
P407
P577
2004-06-01T00:00:00Z